

# Innovation at Work Arkansas



## Research in the Natural State

### *Eli Lilly and AstraZeneca, Jonesboro and Springdale, AR*

The population of Americans with Alzheimer’s disease is predicted to reach 13.8 million by 2050. Eli Lilly and AstraZeneca are conducting phase III clinical trials testing the safety and efficacy of a treatment for early Alzheimer’s disease, which could slow the mental decline associated with the condition and allow patients to maintain independence.

### *Intervexion Therapeutics, Little Rock, AR*

National Institutes of Health (NIH)-funded researchers at Intervexion Therapeutics are working to develop the first vaccine to combat methamphetamine (meth) addiction. The most recent estimate places the economic burden of meth abuse at \$23.4 billion annually in the U.S.

### *University of Arkansas for Medical Sciences, Little Rock, AR*

Researchers at the University of Arkansas are conducting a clinical trial testing nutritional interventions for elderly patients with mild to moderate heart failure. Approximately 6-10% of elderly individuals suffer from heart failure, with a 35% risk of death in the first year after diagnosis. Previous research found amino acid and protein supplements prevent loss of muscle mass, which could reduce heart failure symptoms.

SOURCES: NATIONAL INSTITUTES OF HEALTH (NIH), PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), A RESEARCHIAMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JANUARY 2017, CLINICALTRIALS.GOV.